JP2019065028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019065028A5 JP2019065028A5 JP2018238017A JP2018238017A JP2019065028A5 JP 2019065028 A5 JP2019065028 A5 JP 2019065028A5 JP 2018238017 A JP2018238017 A JP 2018238017A JP 2018238017 A JP2018238017 A JP 2018238017A JP 2019065028 A5 JP2019065028 A5 JP 2019065028A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- use according
- simplex virus
- antibody
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 241000700584 Simplexvirus Species 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 2
- 101150076998 ICP34.5 gene Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000046157 human CSF2 Human genes 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261694963P | 2012-08-30 | 2012-08-30 | |
| US61/694,963 | 2012-08-30 | ||
| US201361846147P | 2013-07-15 | 2013-07-15 | |
| US61/846,147 | 2013-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530096A Division JP6457940B2 (ja) | 2012-08-30 | 2013-08-30 | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019065028A JP2019065028A (ja) | 2019-04-25 |
| JP2019065028A5 true JP2019065028A5 (enExample) | 2019-06-06 |
| JP6656349B2 JP6656349B2 (ja) | 2020-03-04 |
Family
ID=49162279
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530096A Active JP6457940B2 (ja) | 2012-08-30 | 2013-08-30 | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
| JP2018238017A Active JP6656349B2 (ja) | 2012-08-30 | 2018-12-20 | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530096A Active JP6457940B2 (ja) | 2012-08-30 | 2013-08-30 | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10034938B2 (enExample) |
| EP (3) | EP2890714A2 (enExample) |
| JP (2) | JP6457940B2 (enExample) |
| KR (2) | KR20210008155A (enExample) |
| CN (2) | CN114984062A (enExample) |
| AU (3) | AU2013308595C1 (enExample) |
| CA (1) | CA2881851C (enExample) |
| EA (1) | EA201590451A1 (enExample) |
| ES (1) | ES2871910T3 (enExample) |
| HK (1) | HK1211601A1 (enExample) |
| PT (1) | PT3381942T (enExample) |
| WO (1) | WO2014036412A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013308595C1 (en) † | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| CA2947605A1 (en) * | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| WO2016022813A1 (en) * | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| MX391478B (es) | 2014-10-10 | 2025-03-21 | Idera Pharmaceuticals Inc | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer. |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| MX2017008013A (es) * | 2014-12-18 | 2018-03-06 | Amgen Inc | Formulacion congelada estable de virus de herpes simple. |
| KR20170117113A (ko) * | 2015-02-12 | 2017-10-20 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 관문 저해제와 조합한 플리나불린의 용도 |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| WO2016140714A1 (en) * | 2015-03-05 | 2016-09-09 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| EP3294757B1 (en) | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| WO2017004421A1 (en) * | 2015-06-30 | 2017-01-05 | The Trustees Of The University Of Pennsylvania | Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions |
| WO2017013419A1 (en) | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| CN108884159A (zh) | 2015-11-07 | 2018-11-23 | 茂体外尔公司 | 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| DK3400290T5 (da) | 2016-01-08 | 2024-09-23 | Replimune Ltd | Onkolytisk virusstamme |
| WO2017119499A1 (en) * | 2016-01-08 | 2017-07-13 | Momotaro-Gene Inc. | A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| KR20240091084A (ko) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
| EP3471722B1 (en) * | 2016-06-17 | 2023-10-25 | The Trustees of the University of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
| WO2018003995A1 (ja) | 2016-07-01 | 2018-01-04 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| HUE053236T2 (hu) | 2016-09-12 | 2021-06-28 | Targovax Oy | Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére |
| WO2018075447A1 (en) * | 2016-10-19 | 2018-04-26 | The Trustees Of Columbia University In The City Of New York | Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma) |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| IL268305B2 (en) | 2017-02-01 | 2024-08-01 | Beyondspring Pharmaceuticals Inc | Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced |
| US20180271996A1 (en) | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| US20200009204A1 (en) * | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| EP4063859A1 (en) | 2017-04-28 | 2022-09-28 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CN107354136A (zh) * | 2017-06-15 | 2017-11-17 | 杭州睿可特生物科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用 |
| BR112020007494A2 (pt) | 2017-10-27 | 2020-11-03 | Merck Sharp & Dohme Corp. | composições e métodos para tratamento do câncer de fígado |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| CN108635380A (zh) | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| AU2019369340A1 (en) | 2018-10-29 | 2021-05-20 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
| KR20210135532A (ko) * | 2019-03-05 | 2021-11-15 | 암젠 인크 | 암 치료를 위한 종양 용해 바이러스의 용도 |
| TW202102543A (zh) * | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| KR20240102682A (ko) | 2022-12-26 | 2024-07-03 | 한국단자공업 주식회사 | 터미널 및 이 터미널을 구비한 커넥터 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| KR100802403B1 (ko) * | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| US20110118464A1 (en) * | 2009-11-18 | 2011-05-19 | Kaohsiung Medical University | Halogenated xanthine derivatives and precursors thereof for anti-cancer and anti-metastasis activity and preparing method thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US9107887B2 (en) * | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| EP2591796A1 (en) * | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
| EP2806883B1 (en) * | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| AU2013308595C1 (en) † | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| JP6895374B2 (ja) * | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| WO2017013419A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| US20200009204A1 (en) * | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
-
2013
- 2013-08-30 AU AU2013308595A patent/AU2013308595C1/en active Active
- 2013-08-30 EP EP13760221.5A patent/EP2890714A2/en not_active Withdrawn
- 2013-08-30 KR KR1020217001035A patent/KR20210008155A/ko not_active Ceased
- 2013-08-30 WO PCT/US2013/057542 patent/WO2014036412A2/en not_active Ceased
- 2013-08-30 EP EP21188061.2A patent/EP3981791A1/en active Pending
- 2013-08-30 KR KR1020157005928A patent/KR102204525B1/ko active Active
- 2013-08-30 US US14/424,424 patent/US10034938B2/en active Active
- 2013-08-30 CA CA2881851A patent/CA2881851C/en active Active
- 2013-08-30 HK HK15112368.2A patent/HK1211601A1/xx unknown
- 2013-08-30 ES ES18157842T patent/ES2871910T3/es active Active
- 2013-08-30 PT PT181578428T patent/PT3381942T/pt unknown
- 2013-08-30 CN CN202210427262.0A patent/CN114984062A/zh active Pending
- 2013-08-30 CN CN201380045105.2A patent/CN104704002B/zh active Active
- 2013-08-30 EA EA201590451A patent/EA201590451A1/ru unknown
- 2013-08-30 EP EP18157842.8A patent/EP3381942B2/en active Active
- 2013-08-30 JP JP2015530096A patent/JP6457940B2/ja active Active
-
2018
- 2018-06-27 US US16/019,753 patent/US20190060452A1/en not_active Abandoned
- 2018-07-24 AU AU2018208640A patent/AU2018208640A1/en not_active Abandoned
- 2018-12-20 JP JP2018238017A patent/JP6656349B2/ja active Active
-
2020
- 2020-02-13 AU AU2020201051A patent/AU2020201051A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019065028A5 (enExample) | ||
| Bedke et al. | Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma | |
| Beres et al. | Rituximab use in pediatric central demyelinating disease | |
| Malaviya | Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story | |
| JP2015187125A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2019516711A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| Tanasescu et al. | Advances in the treatment of relapsing-remitting multiple sclerosis | |
| JPWO2020249693A5 (enExample) | ||
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| Middleton et al. | Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors | |
| JP2016505572A5 (enExample) | ||
| JP2016526531A5 (enExample) | ||
| RU2015152860A (ru) | Режим введения и составы для аденовирусов типа в | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| Scherl et al. | Review of the safety and efficacy of ustekinumab | |
| JP2019526559A5 (enExample) | ||
| FI3733712T3 (fi) | Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä | |
| Bridel et al. | Update on multiple sclerosis treatments | |
| IL297502A (en) | A method for treating cervical cancer | |
| Bröckelmann et al. | Nivolumab and AVD for early-stage unfavorable Hodgkin lymphoma (NIVAHL) | |
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| IL310909A (en) | Dosing regimens associated with extended release paliperidone injectable formulations |